LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Golf Performance Study Golfer undergoing V02 max profile to establish their basic aerobic fitness. ACTUAL EEG BRAIN SCAN BEFORE &...
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global...
Renowned neuroscience leader to further long-term clinical research strategy and external collaborationsCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion...
•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic...
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE...
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...
– Data showed OP-101 delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and...
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint’s SmartFlow® Neuro CannulaSOLANA BEACH, Calif.,...
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to...
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on...
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...
Press release, Helsinki, 19 July 2022 at 10 AM (EET) Nexstim Receives an NBS System Order from a Finnish Customer...
– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of OP-801 in comparison to TSPO-PET for...